{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:21Z","timestamp":1787026581210,"version":"build-2736575974"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant chemoradiotherapy (nCRT) is recommended as the standard of care for locally advanced esophageal squamous cell carcinoma (ESCC). Adding immunotherapy to nCRT (nICRT) has gained attention in clinical practice. We evaluated the differences in clinicopathologic outcomes and the patterns of lymph node metastasis in patients receiving nCRT and nICRT for locally advanced ESCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 208 ESCC patients who completed transthoracic esophagectomy after neoadjuvant treatment were enrolled. Clinicopathologic parameters and the rates of lymph node metastasis in each station classified using both the eighth edition of the American Joint Committee on Cancer (AJCC) esophageal cancer staging system and the 11th edition of the Japanese Classification of Esophageal Cancer (JCEC) standard were recorded and evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The rates of pathological complete response (pCR) and major pathological response (MPR) were 44.9% in nICRT vs. 37.0% in nCRT (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.263) and 79.5% in nICRT vs. 65.4% in nCRT (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.024), respectively. The common sites of lymph node metastasis after neoadjuvant treatment were station 112pulL (8.3%), followed by station 104L (4.9%), station 7 (4.5%), and station 3a (4.3%), according to the 11th JCEC standard. Compared with nCRT, nICRT can significantly reduce the rates of lymph node metastasis in station 2R (0.8% vs. 4.6%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.039) classified using the AJCC system, and those in station 106recR (0.8% vs. 4.6%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.042) and station 20 (0 vs. 12.5%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.030) classified using the JCEC standard.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>nICRT followed by surgery may lead to a promising pathological response. For patients with lymph node metastasis in certain regions, nICRT should be considered as a better preoperative treatment option.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1700400","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:32:18Z","timestamp":1761111138000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Residual pattern of primary tumor and lymph node in ESCC treated with nCRT with or without pembrolizumab: an analysis from a prospective cohort"],"prefix":"10.3389","volume":"16","author":[{"given":"Xuan","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Xiang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Guang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17048","DOI":"10.1038\/nrdp.2017.48","article-title":"Oesophageal cancer","volume":"3","author":"Smyth","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/JCO.20.03614","article-title":"Ten-Year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial","volume":"39","author":"Eyck","year":"2021","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.1483","article-title":"Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): A phase III multicenter, randomized, open-Label clinical trial","volume":"36","author":"Yang","year":"2018","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","article-title":"Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Ajani","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02500","article-title":"Esophagogastric cancers: integrating immunotherapy therapy into current practice","volume":"40","author":"Patel","year":"2022","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.21037\/atm-21-5381","article-title":"Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1)","volume":"9","author":"Zhang","year":"2021","journal-title":"Ann Transl Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-22-131","article-title":"Toripalimab combined with docetaxel and cisplatin neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a single-center, single-arm clinical trial (ESONICT-2)","volume":"13","author":"Gao","year":"2022","journal-title":"J Gastrointest Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"106680","DOI":"10.1016\/j.ijsu.2022.106680","article-title":"Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)","volume":"103","author":"Yan","year":"2022","journal-title":"Int J Surg"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.953229","article-title":"Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy","volume":"13","author":"Qiao","year":"2022","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s12957-021-02446-5","article-title":"Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study","volume":"19","author":"Yang","year":"2021","journal-title":"World J Surg Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1031171","article-title":"Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40425-018-0361-7","article-title":"Radiation therapy and PD-1\/PD-L1 blockade: the clinical development of an evolving anticancer combination","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0413","article-title":"Pembrolizumab in combination with neoadjuvant chemoradiotherapy for patients with resectable adenocarcinoma of the gastroesophageal junction","volume":"28","author":"Zhu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4443","article-title":"Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: A single-arm phase II feasibility trial (PERFECT)","volume":"27","author":"van den Ende","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.11.039","article-title":"Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)","volume":"144","author":"Li","year":"2021","journal-title":"Eur J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjon.2021.11.003","article-title":"Preoperative pembrolizumab combined with chemoradiotherapy for esophageal squamous cell carcinoma: Trial design","volume":"9","author":"Zheng","year":"2022","journal-title":"JTCVS Open"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.2186","article-title":"Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials","volume":"32","author":"Oppedijk","year":"2014","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/BF00316810","article-title":"Esophageal squamous cell carcinoma: pathology and prognosis","volume":"18","author":"Ide","year":"1994","journal-title":"World J Surg"},{"key":"B24","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41571-023-00757-y","article-title":"Improving outcomes in patients with oesophageal cancer","volume":"20","author":"Shah","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jtho.2016.10.016","article-title":"Cancer of the esophagus and esophagogastric junction: an eighth edition staging primer","volume":"12","author":"Rice","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B26","article-title":"Japanese classification of esophageal cancer","volume-title":"Esophagus","year":"2017"},{"key":"B27","article-title":"Japanese classification of esophageal cancer","volume-title":"Esophagus","year":"2017"},{"key":"B28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13014-024-02581-9","article-title":"Characterization and dosimetric predictors for absolute lymphocyte count changes during neoadjuvant chemoradiotherapy with or without pembrolizumab for esophageal squamous cell carcinoma: an analysis of a prospective cohort","volume":"20","author":"Qi","year":"2025","journal-title":"Radiat Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1186\/s12885-024-12774-w","article-title":"The addition of pembrolizumab to neoadjuvant chemoradiotherapy did not increase the risk of developing postoperative anastomotic leakage for ESCC: an analysis from a prospective cohort","volume":"24","author":"Qi","year":"2024","journal-title":"BMC Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14898","article-title":"Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort","volume":"14","author":"Qi","year":"2023","journal-title":"Thorac Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1186\/s12885-022-09721-y","article-title":"Effects of pre-operative enteral immunonutrition for esophageal cancer patients treated with neoadjuvant chemoradiotherapy: protocol for a multicenter randomized controlled trial (point trial, pre-operative immunonutrition therapy)","volume":"22","author":"Cao","year":"2022","journal-title":"BMC Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20916","article-title":"Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation","volume":"103","author":"Chirieac","year":"2005","journal-title":"Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.2373","article-title":"Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial","volume":"156","author":"Yang","year":"2021","journal-title":"JAMA Surg"},{"key":"B34","doi-asserted-by":"publisher","first-page":"17562848221148250","DOI":"10.1177\/17562848221148250","article-title":"Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer","volume":"16","author":"Hirose","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41467-022-28408-3","article-title":"Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)","volume":"13","author":"Xu","year":"2022","journal-title":"Nat Commun"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35561","article-title":"Combination of immune checkpoint inhibitors and radiotherapy in locally advanced esophagogastric junction adenocarcinoma: A review","volume":"130","author":"Abyaneh","year":"2024","journal-title":"Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.jtcvs.2020.11.106","article-title":"Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer","volume":"161","author":"Sihag","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000002389","article-title":"Impact of lymph node yield on overall survival in patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy for cancer: A population-based cohort study in the Netherlands","volume":"266","author":"Visser","year":"2017","journal-title":"Ann Surg"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1051841","article-title":"Neoadjuvant immunotherapy for resectable esophageal cancer: A review","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s00432-024-05967-0","article-title":"Frequency and distribution pattern of lymph node metastasis after neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma","volume":"150","author":"Zhou","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-13634-w","article-title":"Patterns and influence of lymph nodal metastases after neoadjuvant chemotherapy and surgery for thoracic esophageal squamous cell carcinoma","volume":"30","author":"Sun","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2020.09.042","article-title":"Residual tumor characteristics of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy","volume":"162","author":"Tang","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00276-007-0257-6","article-title":"Extramural lymphatic drainage from the thoracic esophagus based on minute cadaveric dissections: fundamentals for the sentinel node navigation surgery for the thoracic esophageal cancers","volume":"29","author":"Saito","year":"2007","journal-title":"Surg Radiol Anat"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1616247","article-title":"Tertiary lymphoid structures correlate with the therapeutic efficacy and prognosis of resectable esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy plus immunotherapy","volume":"16","author":"Zhai","year":"2025","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1700400\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:32:20Z","timestamp":1761111140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1700400\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2025.1700400"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1700400","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"article-number":"1700400"}}